News coverage about Zymeworks (NASDAQ:ZYME) has trended somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Zymeworks earned a news impact score of 0.18 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.2847355852824 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news headlines that may have impacted Accern Sentiment’s rankings:
- U.S. STOCKS ON THE MOVE-Mattel, GE, Nova, GGP Inc (timesofindia.indiatimes.com)
- Zymeworks, Janssen in $1.45B Antibody Licensing Deal (sciencebusiness.technewslit.com)
- Zymeworks Inc. (ZYME) Is Suring On License Agreement (rttnews.com)
- Zymeworks to Present at Upcoming 2017 Stifel Healthcare Conference (finance.yahoo.com)
- 28 Stocks Moving In Monday’s Mid-Day Session (feeds.benzinga.com)
A number of research firms recently issued reports on ZYME. Zacks Investment Research raised Zymeworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Barclays PLC reaffirmed an “underweight” rating and issued a $8.00 target price on shares of Zymeworks in a research report on Thursday, September 7th. Scotiabank downgraded Zymeworks from an “overweight” rating to an “underweight” rating in a research report on Thursday, September 7th. Finally, Cormark reaffirmed a “buy” rating on shares of Zymeworks in a research report on Saturday, September 30th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $16.00.
Zymeworks (ZYME) traded up $1.70 during trading on Monday, reaching $8.57. The company had a trading volume of 310,431 shares, compared to its average volume of 6,247. Zymeworks has a fifty-two week low of $6.25 and a fifty-two week high of $14.25.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.chaffeybreeze.com/2017/11/13/zymeworks-zyme-receives-daily-news-impact-score-of-0-18.html.
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company’s ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company’s platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins.
Receive News & Ratings for Zymeworks Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks Inc and related companies with MarketBeat.com's FREE daily email newsletter.